Published in Diabetes Care on March 23, 2010
Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. J Am Soc Nephrol (2012) 2.58
Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study. Kidney Int (2014) 1.80
Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria. Diabetes Care (2013) 1.62
Uric acid and chronic kidney disease: which is chasing which? Nephrol Dial Transplant (2013) 1.55
Serum uric acid predicts vascular complications in adults with type 1 diabetes: the coronary artery calcification in type 1 diabetes study. Acta Diabetol (2014) 1.48
Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function. Diabetes Care (2011) 1.23
Uric acid as a target of therapy in CKD. Am J Kidney Dis (2012) 1.22
Uric acid as a mediator of diabetic nephropathy. Semin Nephrol (2011) 1.11
Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol study. Curr Diab Rep (2013) 1.09
Tissue transcriptome-driven identification of epidermal growth factor as a chronic kidney disease biomarker. Sci Transl Med (2015) 1.03
Can existing drugs approved for other indications retard renal function decline in patients with type 1 diabetes and nephropathy? Semin Nephrol (2012) 1.02
Diabetic nephropathy - complications and treatment. Int J Nephrol Renovasc Dis (2014) 1.01
Fructose and uric acid in diabetic nephropathy. Diabetologia (2015) 0.99
Urinary cystatin C and tubular proteinuria predict progression of diabetic nephropathy. Diabetes Care (2012) 0.99
Early diabetic nephropathy in type 1 diabetes: new insights. Curr Opin Endocrinol Diabetes Obes (2014) 0.98
Serum uric acid and insulin sensitivity in adolescents and adults with and without type 1 diabetes. J Diabetes Complications (2013) 0.98
Progressive renal decline: the new paradigm of diabetic nephropathy in type 1 diabetes. Diabetes Care (2015) 0.97
Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol (2015) 0.94
Serum levels of advanced glycation endproducts and other markers of protein damage in early diabetic nephropathy in type 1 diabetes. PLoS One (2012) 0.91
Linking uric acid metabolism to diabetic complications. World J Diabetes (2014) 0.90
Management of Chronic Kidney Disease: The Relationship Between Serum Uric Acid and Development of Nephropathy. Adv Ther (2015) 0.90
Uric acid transporter ABCG2 is increased in the intestine of the 5/6 nephrectomy rat model of chronic kidney disease. Clin Exp Nephrol (2013) 0.86
Increased plasma kidney injury molecule-1 suggests early progressive renal decline in non-proteinuric patients with type 1 diabetes. Kidney Int (2016) 0.85
Clinical therapeutic strategies for early stage of diabetic kidney disease. World J Diabetes (2014) 0.83
Uric acid and chronic kidney disease: A time to act? World J Nephrol (2013) 0.83
Uric acid is not associated with decline in renal function or time to renal replacement therapy initiation in a referred cohort of patients with Stage III, IV and V chronic kidney disease. Nephrol Dial Transplant (2015) 0.83
Horizon 2020 in Diabetic Kidney Disease: The Clinical Trial Pipeline for Add-On Therapies on Top of Renin Angiotensin System Blockade. J Clin Med (2015) 0.82
Comorbidities in patients with crystal diseases and hyperuricemia. Rheum Dis Clin North Am (2014) 0.81
Diabetes: Lowering serum uric acid levels to prevent kidney failure. Nat Rev Nephrol (2011) 0.81
Relationship between Serum Uric Acid Levels and Chronic Kidney Disease in a Japanese Cohort with Normal or Mildly Reduced Kidney Function. PLoS One (2015) 0.80
Clinical predictive factors in diabetic kidney disease progression. J Diabetes Investig (2016) 0.79
Transcriptome analysis of proximal tubular cells (HK-2) exposed to urines of type 1 diabetes patients at risk of early progressive renal function decline. PLoS One (2013) 0.78
Serum Uric Acid and Progression of Kidney Disease: A Longitudinal Analysis and Mini-Review. PLoS One (2017) 0.77
Effects of xanthine oxidase inhibition with febuxostat on the development of nephropathy in experimental type 2 diabetes. Br J Pharmacol (2016) 0.77
Role of elevated serum uric acid levels at the onset of overt nephropathy in the risk for renal function decline in patients with type 2 diabetes. J Diabetes Investig (2014) 0.77
New Pathogenic Concepts and Therapeutic Approaches to Oxidative Stress in Chronic Kidney Disease. Oxid Med Cell Longev (2016) 0.76
Influence of changes in serum uric acid levels on renal function in elderly patients with hypertension: a retrospective cohort study with 3.5-year follow-up. BMC Geriatr (2016) 0.76
Potential Role of Serum and Urinary Biomarkers in Diagnosis and Prognosis of Diabetic Nephropathy. Can J Kidney Health Dis (2017) 0.76
Proteomics for prediction of disease progression and response to therapy in diabetic kidney disease. Diabetologia (2016) 0.75
Uricosuric targets of tranilast. Pharmacol Res Perspect (2017) 0.75
Diabetes: Serum uric acid level is associated with early GFR loss in type 1 diabetes. Nat Rev Nephrol (2010) 0.75
Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes. Kidney Int (2017) 0.75
Increased Serum Uric Acid Level Is a Risk Factor for Left Ventricular Hypertrophy but Not Independent of eGFR in Patients with Type 2 Diabetic Kidney Disease. J Diabetes Res (2017) 0.75
Uric acid in the pathogenesis of metabolic, renal, and cardiovascular diseases: A review. J Adv Res (2016) 0.75
Asymptomatic hyperuricemia and chronic kidney disease: Narrative review of a treatment controversial. J Adv Res (2017) 0.75
Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis (2008) 15.04
Regression of microalbuminuria in type 1 diabetes. N Engl J Med (2003) 7.67
Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med (2005) 7.24
Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc (1985) 7.02
Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. J Am Soc Nephrol (2007) 4.48
Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis (2006) 4.26
Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med (2009) 4.05
Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation (2002) 3.72
Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor intervention trial. J Am Soc Nephrol (2006) 3.51
Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study. J Am Soc Nephrol (2005) 3.48
Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol (2008) 3.42
Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol (2002) 3.37
Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int Urol Nephrol (2007) 3.06
In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. Kidney Int (2010) 2.82
Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis (2004) 2.73
Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension (2000) 2.55
The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? Diabetes (2000) 2.41
Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study. Diabetes (2009) 1.76
Risk factors for development of decreased kidney function in a southeast Asian population: a 12-year cohort study. J Am Soc Nephrol (2005) 1.76
High-normal serum uric acid is associated with impaired glomerular filtration rate in nonproteinuric patients with type 1 diabetes. Clin J Am Soc Nephrol (2008) 1.74
Serial measurements of cystatin C are more accurate than creatinine-based methods in detecting declining renal function in type 1 diabetes. Diabetes Care (2008) 1.67
Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis (1998) 1.53
Integrating albuminuria and GFR in the assessment of diabetic nephropathy. Nat Rev Nephrol (2009) 1.19
Identification and importance of brown adipose tissue in adult humans. N Engl J Med (2009) 20.57
Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med (2012) 14.99
Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. Clin Chem (2005) 8.93
Meta-analysis of genome-wide association study data identifies additional type 1 diabetes risk loci. Nat Genet (2008) 7.71
Regression of microalbuminuria in type 1 diabetes. N Engl J Med (2003) 7.67
Ethical and practical guidelines for reporting genetic research results to study participants: updated guidelines from a National Heart, Lung, and Blood Institute working group. Circ Cardiovasc Genet (2010) 6.74
Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med (2005) 5.78
Reporting genetic results in research studies: summary and recommendations of an NHLBI working group. Am J Med Genet A (2006) 4.56
Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. J Am Soc Nephrol (2007) 4.48
Clostridium difficile ribotype does not predict severe infection. Clin Infect Dis (2012) 4.34
Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. Nat Med (2009) 3.97
Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study. J Am Soc Nephrol (2005) 3.48
Performance in Measurement of Serum Cystatin C by Laboratories Participating in the College of American Pathologists 2014 CYS Survey. Arch Pathol Lab Med (2015) 3.36
Leukocyte telomeres are longer in African Americans than in whites: the National Heart, Lung, and Blood Institute Family Heart Study and the Bogalusa Heart Study. Aging Cell (2008) 3.24
Genome-wide association scan for diabetic nephropathy susceptibility genes in type 1 diabetes. Diabetes (2009) 3.16
Genetics of Kidneys in Diabetes (GoKinD) study: a genetics collection available for identifying genetic susceptibility factors for diabetic nephropathy in type 1 diabetes. J Am Soc Nephrol (2006) 3.12
Residual insulin production and pancreatic ß-cell turnover after 50 years of diabetes: Joslin Medalist Study. Diabetes (2010) 2.94
In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. Kidney Int (2010) 2.82
Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Ann Intern Med (2006) 2.81
Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. J Am Soc Nephrol (2012) 2.75
Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. J Am Soc Nephrol (2012) 2.58
Risk for ESRD in type 1 diabetes remains high despite renoprotection. J Am Soc Nephrol (2011) 2.50
Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension (2012) 2.42
Plasma fatty acid composition and incidence of diabetes in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Clin Nutr (2003) 2.41
Method for mapping population-based case-control studies: an application using generalized additive models. Int J Health Geogr (2006) 2.37
Roadmap for harmonization of clinical laboratory measurement procedures. Clin Chem (2011) 2.34
Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med (2007) 2.23
A haplotype at the adiponectin locus is associated with obesity and other features of the insulin resistance syndrome. Diabetes (2002) 2.15
Dietary linolenic acid is inversely associated with calcified atherosclerotic plaque in the coronary arteries: the National Heart, Lung, and Blood Institute Family Heart Study. Circulation (2005) 2.03
Protection from retinopathy and other complications in patients with type 1 diabetes of extreme duration: the joslin 50-year medalist study. Diabetes Care (2011) 2.00
Genetic influences of adiponectin on insulin resistance, type 2 diabetes, and cardiovascular disease. Diabetes (2007) 1.98
Variants in the CD36 gene associate with the metabolic syndrome and high-density lipoprotein cholesterol. Hum Mol Genet (2008) 1.98
Spatial analysis of lung, colorectal, and breast cancer on Cape Cod: an application of generalized additive models to case-control data. Environ Health (2005) 1.94
Determinants of progression from microalbuminuria to proteinuria in patients who have type 1 diabetes and are treated with angiotensin-converting enzyme inhibitors. Clin J Am Soc Nephrol (2007) 1.92
Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics (2010) 1.90
Skin-derived fibroblasts from long-lived species are resistant to some, but not all, lethal stresses and to the mitochondrial inhibitor rotenone. Aging Cell (2006) 1.89
Interaction between poor glycemic control and 9p21 locus on risk of coronary artery disease in type 2 diabetes. JAMA (2008) 1.88
Exclusion of polymorphisms in carnosinase genes (CNDP1 and CNDP2) as a cause of diabetic nephropathy in type 1 diabetes: results of large case-control and follow-up studies. Diabetes (2008) 1.82
Confirmation of genetic associations at ELMO1 in the GoKinD collection supports its role as a susceptibility gene in diabetic nephropathy. Diabetes (2009) 1.80
Polymorphisms in the nonmuscle myosin heavy chain 9 gene (MYH9) are associated with albuminuria in hypertensive African Americans: the HyperGEN study. Am J Nephrol (2009) 1.80
Genetic analysis of albuminuria in aging mice and concordance with loci for human diabetic nephropathy found in a genome-wide association scan. Kidney Int (2009) 1.78
Hemochromatosis and Iron Overload Screening (HEIRS) study design for an evaluation of 100,000 primary care-based adults. Am J Med Sci (2003) 1.76
NHANES monitoring of serum 25-hydroxyvitamin D: a roundtable summary. J Nutr (2010) 1.74
High-normal serum uric acid is associated with impaired glomerular filtration rate in nonproteinuric patients with type 1 diabetes. Clin J Am Soc Nephrol (2008) 1.74
Biological variability of transferrin saturation and unsaturated iron-binding capacity. Am J Med (2007) 1.72
Mupirocin-based decolonization of Staphylococcus aureus carriers in residents of 2 long-term care facilities: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis (2003) 1.69
Spatial-temporal analysis of breast cancer in upper Cape Cod, Massachusetts. Int J Health Geogr (2008) 1.68
Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetyl-β-D-glucosaminidase. Kidney Int (2010) 1.67
Inclusion of 30-day postdischarge detection triples the incidence of hospital-onset methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol (2011) 1.63
Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria. Diabetes Care (2013) 1.62
Serum concentrations of markers of TNFalpha and Fas-mediated pathways and renal function in nonproteinuric patients with type 1 diabetes. Clin J Am Soc Nephrol (2008) 1.62
The pseudokinase tribbles homolog 3 interacts with ATF4 to negatively regulate insulin exocytosis in human and mouse beta cells. J Clin Invest (2010) 1.61
Gene expression patterns in calorically restricted mice: partial overlap with long-lived mutant mice. Mol Endocrinol (2002) 1.61
Genome scan of glomerular filtration rate and albuminuria: the HyperGEN study. Nephrol Dial Transplant (2006) 1.59
Urinary peptidome may predict renal function decline in type 1 diabetes and microalbuminuria. J Am Soc Nephrol (2009) 1.57
A common haplotype at the CD36 locus is associated with high free fatty acid levels and increased cardiovascular risk in Caucasians. Hum Mol Genet (2004) 1.56
Pharmacogenetic association of hypertension candidate genes with fasting glucose in the GenHAT Study. J Hypertens (2010) 1.55
Trends in the prevalence of reduced GFR in the United States: a comparison of creatinine- and cystatin C-based estimates. Am J Kidney Dis (2013) 1.54
Poly(ADP-Ribose) polymerase is activated in subjects at risk of developing type 2 diabetes and is associated with impaired vascular reactivity. Circulation (2002) 1.52
An IL-6 haplotype on human chromosome 7p21 confers risk for impaired renal function in type 2 diabetic patients. Kidney Int (2008) 1.51
Prenatal and early childhood exposure to tetrachloroethylene and adult vision. Environ Health Perspect (2012) 1.49
Breast cancer risk and historical exposure to pesticides from wide-area applications assessed with GIS. Environ Health Perspect (2004) 1.49
Cathepsin L activity controls adipogenesis and glucose tolerance. Nat Cell Biol (2007) 1.46
Clinical factors associated with resistance to microvascular complications in diabetic patients of extreme disease duration: the 50-year medalist study. Diabetes Care (2007) 1.46
Epidemic of end-stage renal disease in people with diabetes in the United States population: do we know the cause? Kidney Int (2005) 1.45
HFE C282Y homozygosity is associated with lower total and low-density lipoprotein cholesterol: The hemochromatosis and iron overload screening study. Circ Cardiovasc Genet (2009) 1.45